Dispersible tablet formulation of dolutegravir (Tivicay) in paediatric patients aged at least four weeks and weighing at least 3kg approved in EU

The EU authorisation makes dolutegravir first integrase inhibitor available as a dispersible tablet for this population. Approval was based ongoing P1093 and ODYSSEY studies, being conducted in collaboration with international paediatric research networks, IMPACT and PENTA-ID.

Source:

PharmaTimes